Hongji Medical Secures Hundreds of Millions in RMB Financing Led by Qiming Venture Partners to Advance Disposable Endoscopy Innovation

VCBeat has learned that, recently,SZ HugeMed MED TECH DEV CO.,LTDSuccessfully completed a new round of financing, raising hundreds of millions of RMB. This round was led byQiming Venture PartnersExclusive Investment.

The proceeds from this financing round will be used to continue advancing the commercial promotion of launched single-use endoscope products, as well as the research and development and production of new pipelines. It will also strengthen the construction of SZ HugeMed’s production base and the layout of its global marketing network and channels, further enhancing the company’s comprehensive competitive advantage in the field of single-use endoscopy.

Shenzhen HugeMed Medical Co., Ltd., established in 2014, is a national-level “Specialized, Refined, Differential, and Innovative” Little Giant enterprise focused on the research and development, manufacturing, sales, and after-sales service of medical devices. The company boasts an efficient team with over a decade of experience in medical device R&D. Its products provide comprehensive solutions in the field of endoscopy for clinical surgery, emergency care, anesthesia, respiratory medicine, pediatrics, intensive care units (ICUs), operating rooms, ambulances, and outdoor emergency rescue.

Shenzhen HugeMed’s products are widely recognized in the market, having obtained CE, FDA, BSI, NMPA, and ISO 13485 certifications. The company’s products are exported to more than 100 countries and regions worldwide, receiving positive feedback in global markets. Currently, Shenzhen HugeMed ranks among the top domestic exporters of airway management products and is listed among the top ten globally.

Shenzhen HugeMed will continue to develop new disposable endoscope pipelines, striving to achieve comprehensive coverage of visualized, non-invasive diagnosis and treatment across all natural human body cavities. The company is committed to advancing China’s disposable endoscopy industry, aiming to achieve leapfrog development and establish itself as a globally competitive, renowned brand.

Hu Jifan, Chairman of Shenzhen HugeMedstated: “We are grateful for the investors’ recognition. This round of financing is highly significant to our company, as it will drive R&D of our new pipeline and commercial promotion of our launched products, accelerate the market launch of products under development, facilitate rapid expansion into both domestic and international markets, and significantly enhance our brand influence. With the strong support of Qiming Venture Partners, we are confident that our company will deliver greater value to technological innovation in China and provide more convenient and efficient products and services to patients worldwide.”

Hu Xubo, Managing Partner at Qiming Venture Partnersstated: “We remain bullish on the long-term growth potential of China’s medical device industry. In recent years, advances in technology, enhanced engineering capabilities, and a deeper understanding of global clinical needs have all helped SZ HugeMed MED TECH DEV CO.,LTD introduce more competitive single-use endoscope products to customers worldwide. We are pleased to support the company in developing better products for the global market.”

Qiming Venture Partners was established in 2006 and has successively set up offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore.

Currently, Qiming Venture Partners manages 11 U.S. dollar funds and seven RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.

To date, Qiming Venture Partners has invested in more than 530 high-growth innovative companies. Among these, over 200 have either listed on major exchanges—including the New York Stock Exchange (NYSE), NASDAQ, the Hong Kong Stock Exchange (HKEX), the Shanghai Stock Exchange (SSE), and the Shenzhen Stock Exchange (SZSE)—or exited through mergers and acquisitions. Additionally, more than 70 of its portfolio companies have been recognized as industry-leading unicorns or super unicorns.